Tumor 英 /'tju:mə(r)/ 美 /'tjʊmɚ/
释 义 n. 肿瘤；肿块；赘生物
例 句 Therefore, in early cancer, immunosuppression may not be systemic, but it may be there in the tumor itself. 因此，在癌症早期，免疫抑制可能不是全身性的，但可能存在于肿瘤局部。
Lysis 英 /'laɪsɪs/ 美 /'laɪsɪs/
释 义 n. （生物）溶胞，溶菌；溶解，分解；（发烧等生病过程）消退
同根词 lysogenic adj. 生成细胞溶素的；溶原的；产噬的；lysozyme n. 溶解酵素；lysin n. 细胞溶解酶；lysogenicity n. 致溶解性；溶源性
例 句 Methods: The changing of platelet aggregation rate, the thrombus weight, the content of fibrinogen and the euglobulin lysis time were determined after SEF iv on rabbit and mice. 方法：采用家兔、小鼠静脉注射，并测定其血小板最大聚集率、血栓重量、纤维蛋白原含量及球蛋白溶解时间的变化。
Syndrome 英 /'sɪndrəʊm/ 美 /'sɪndrəm/
释 义 n. [临床] 综合症状；并发症状；校验子；并发位
例 句 "We do not have future data on these girls and so we can only speculate that girls in the high risk group might develop metabolic syndrome, heart disease or type-2 diabetes, " she adds. 她补充说：“由于我们并没有这些女孩的未来的跟踪数据，所有我们仅能推测那些有高风险的女孩可能发展为代谢综合征，心脏病或2型糖尿病。”
作者： Peter Hillmen
期刊：J. Clin. Oncol.
In early studies, venetoclax showed unexpected efficacy as monotherapy, with a proportion of patients with high-risk Chronic lymphocytic leukemia (CLL) achieving eradication of measurable residual disease (MRD) to either venetoclax monotherapy or the combination of venetoclax with rituximab. Venetoclax as a single agent is approved by the FDA for patients with CLL who have received at least one prior therapy and by the EMA for previously untreated patients with CLL in the presence of chromosome del(17p) or TP53 mutations and for patients with relapsed CLL with or without del(17p) or TP53 mutations who experience treatment failure with a BCR pathway inhibitor and CIT. Both the FDA and the EMA have approved venetoclax in combination with rituximab in patients with relapsed CLL who have received at least one prior treatment. Venetoclax is generally well tolerated but can lead to GI adverse effects (nausea and diarrhea) and neutropenia. The most common adverse events (AEs) experienced at grade 3 and higher are neutropenia, infection, and anemia. Tumor lysis syndrome (TLS) occasionally occurs in the first month of venetoclax, but with initial dosing commencing at 20 mg/d and ramping up each week to the full dose of 400 mg/d, biochemical TLS occurs in 5% of patients, and clinical TLS is rare.